Guillaume Dureau

Enrichment Technology Co. Ltd. designs, develops and supplies gas centrifuge technology used for the enrichment of uranium. They develop, manufacture, supply and install gas centrifuges. The company was founded in October 2003 and is headquartered in Chester, the United Kingdom.

Areva SA engages in the energy industry. Its products include solutions for power generation, electricity transmission, and distribution. The company was founded on November 12, 1971 and is headquartered in Paris, France.

World Nuclear Association operates an international organization that promotes nuclear power and supports the companies that comprise the global nuclear industry. The company was founded in 1975 and is headquartered in London, the United Kingdom.

Orano UK Ltd. is a holding company that operates subsidiaries engaged in the transmission and distribution of renewable energy. Orano is based in Abingdon, UK. The British company is ultimately controlled by the Government of France.

Part of Enrichment Technology Co. Ltd., the company is a German-based company located in Julich, Germany. The company designs, develops, and supplies gas centrifuge technology used for the enrichment of uranium. The CEO of the company is Reinhard Hinterreither.

Orano Projets SASU is a nuclear fuel cycle engineering expert that provides services to both internal and external customers. The company is based in Châtillon, France and was founded in 2015. The French company's services include operator support engineering and comprehensive EPCM missions. The company is also expanding its nuclear business outside the fuel cycle and into new markets such as health, pharmaceuticals, biotechnologies, defense, and other industries. Orano Projets has 1,600 employees worldwide and is ultimately controlled by the Government of France.

Orano Med SAS is a French biotechnology company that utilizes nuclear technology to develop new therapies for cancer patients with resistant forms of cancer. The company is based in Châtillon, France, and the CEO of the company is Julien Dodet. The company specializes in targeted alpha therapy treatments, which combines biological molecules to target cancer cells with the properties of lead-212 (212pb) to destroy them while limiting the impact on surrounding healthy cells. Orano Med has formed collaborations with prestigious institutions and biopharmaceutical companies to develop several treatments using 212pb combined with various targeting agents. The company has 212pb manufacturing facilities, laboratories, and R&D centers in France and the United States and is currently investing to expand its GMP-manufacturing capacities for 212pb radiolabeled pharmaceuticals. Orano Med is ultimately controlled by the Government of France.